

**PI3KCG Antibody (C-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP8021b****Specification**

---

**PI3KCG Antibody (C-term) Blocking Peptide - Product Information**Primary Accession  
Other Accession[P48736](#)  
[NP\\_002640](#)**PI3KCG Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 5294**Other Names**

Phosphatidylinositol 4, 5-bisphosphate 3-kinase catalytic subunit gamma isoform, PI3-kinase subunit gamma, PI3K-gamma, PI3Kgamma, PtdIns-3-kinase subunit gamma, Phosphatidylinositol 4, 5-bisphosphate 3-kinase 110 kDa catalytic subunit gamma, PtdIns-3-kinase subunit p110-gamma, p110gamma, Phosphoinositide-3-kinase catalytic gamma polypeptide, Serine/threonine protein kinase PIK3CG, p120-PI3K, PIK3CG

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP8021b](/product/products/AP8021b) was selected from the C-term region of human PI3KCG. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**PI3KCG Antibody (C-term) Blocking Peptide - Protein Information****Name** PIK3CG**Function**

Phosphoinositide-3-kinase (PI3K) that phosphorylates PtdIns(4,5)P<sub>2</sub> (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP<sub>3</sub>). PIP<sub>3</sub> plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Links G-protein coupled receptor activation to PIP<sub>3</sub> production. Involved in immune, inflammatory and allergic responses. Modulates leukocyte chemotaxis to inflammatory sites and in response to chemoattractant agents. May control leukocyte polarization and migration by

regulating the spatial accumulation of PIP3 and by regulating the organization of F-actin formation and integrin-based adhesion at the leading edge. Controls motility of dendritic cells. Together with PIK3CD is involved in natural killer (NK) cell development and migration towards the sites of inflammation. Participates in T-lymphocyte migration. Regulates T- lymphocyte proliferation, activation, and cytokine production. Together with PIK3CD participates in T-lymphocyte development. Required for B- lymphocyte development and signaling. Together with PIK3CD participates in neutrophil respiratory burst. Together with PIK3CD is involved in neutrophil chemotaxis and extravasation. Together with PIK3CB promotes platelet aggregation and thrombosis. Regulates alpha-IIb/beta-3 integrins (ITGA2B/ ITGB3) adhesive function in platelets downstream of P2Y12 through a lipid kinase activity-independent mechanism. May have also a lipid kinase activity-dependent function in platelet aggregation. Involved in endothelial progenitor cell migration. Negative regulator of cardiac contractility. Modulates cardiac contractility by anchoring protein kinase A (PKA) and PDE3B activation, reducing cAMP levels. Regulates cardiac contractility also by promoting beta-adrenergic receptor internalization by binding to GRK2 and by non- muscle tropomyosin phosphorylation. Also has serine/threonine protein kinase activity: both lipid and protein kinase activities are required for beta-adrenergic receptor endocytosis. May also have a scaffolding role in modulating cardiac contractility. Contributes to cardiac hypertrophy under pathological stress. Through simultaneous binding of PDE3B to RAPGEF3 and PIK3R6 is assembled in a signaling complex in which the PI3K gamma complex is activated by RAPGEF3 and which is involved in angiogenesis.

**Cellular Location**

Cytoplasm. Cell membrane

**Tissue Location**

Pancreas, skeletal muscle, liver and heart.

**PI3KCG Antibody (C-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**PI3KCG Antibody (C-term) Blocking Peptide - Images****PI3KCG Antibody (C-term) Blocking Peptide - Background**

PI3KCG belongs to the pi3/pi4-kinase family of proteins. The gene product is an enzyme that phosphorylates phosphoinositides on the 3-hydroxyl group of the inositol ring. It is an important modulator of extracellular signals, including those elicited by E-cadherin-mediated cell-cell adhesion, which plays an important role in maintenance of the structural and functional integrity of epithelia. In addition to its role in promoting assembly of adherens junctions, the protein is thought to play a pivotal role in the regulation of cytotoxicity in NK cells.

**PI3KCG Antibody (C-term) Blocking Peptide - References**

Resendiz, J.C., et al., Mol. Pharmacol. 63(3):639-645 (2003).Francois, F., et al., J. Virol. 77(4):2539-2549 (2003).Chandrasekar, N., et al., Oncogene 22(3):392-400 (2003).Ishibashi, Y., et al., Cell. Microbiol. 4(12):825-833 (2002).Semba, S., et al., Clin. Cancer Res. 8(12):3824-3831 (2002).